Large Chinese CROs To Benefit From Continued Outsourcing Trend, CRO Surveys Say
This article was originally published in PharmAsia News
Executive Summary
As Big Pharma continues its restructuring initiatives to outsource services to lower-cost emerging markets, Chinese and U.S. contract research organizations with the largest footprints and broadest capabilities will benefit from the ongoing trend, according to two recently released surveys on the CRO industry